Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?

Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?

Introduction: Whilst the addition of rituximab, a humanized monoclonal antibody to standard CHOP chemotherapy (R-CHOP) has improved the outcomes of DLBCL, the validity of the previously identified prognostic index based on clinical parameters is questioned. It is conceivable that prognostic model ma...

Full description

Bibliographic Details
Main Authors: WM Tai MBBS(S'pore), MRCP(UK), PL Tang MBBS(Melb), MRCP(Edin), YX Koo MBBS(S'pore), X Hou BSci, KW Tay MBBS(S'pore), ABIM Med Onc(USA), R Quek MBBS(S'pore), MRCP(UK), M Tao MBBS(Lond), MRCP(UK), ST Lim MBBS(S'pore), MRCP(UK)
Format: Article
Language:English
Published: SAGE Publishing 2011-03-01
Series:Proceedings of Singapore Healthcare
Online Access:https://doi.org/10.1177/201010581102000108

Internet

https://doi.org/10.1177/201010581102000108

Similar Items